Venture Fund Ix, L.P.Atlas ... Net Worth

The estimated Net Worth of Venture Fund Ix, L.P.Atlas ... is at least $36.4 Million dollars as of 17 December 2020. Venture Atlas owns over 1,700,000 units of Surface Oncology Inc stock worth over $3,151,635 and over the last 8 years Venture sold SURF stock worth over $33,206,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Atlas SURF stock SEC Form 4 insiders trading

Venture has made over 4 trades of the Surface Oncology Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Venture sold 1,700,000 units of SURF stock worth $30,770,000 on 17 December 2020.

The largest trade Venture's ever made was selling 1,700,000 units of Surface Oncology Inc stock on 17 December 2020 worth over $30,770,000. On average, Venture trades about 340,675 units every 210 days since 2016. As of 17 December 2020 Venture still owns at least 2,945,453 units of Surface Oncology Inc stock.

You can see the complete history of Venture Atlas stock trades at the bottom of the page.

What's Venture Atlas's mailing address?

Venture's mailing address filed with the SEC is 25 First St, Cambridge, MA 02141, USA.

Insiders trading at Surface Oncology Inc

Over the last 6 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.

What does Surface Oncology Inc do?

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww

Complete history of Venture Atlas stock trades at Intellia Therapeutics Inc, Unum Therapeutics, and Surface Oncology Inc

Surface Oncology Inc executives and stock owners

Surface Oncology Inc executives and other stock owners filed with the SEC include:

• J. Jeffrey Goater,
  President, Chief Executive Officer, Director
• Vito Palombella,
  Chief Scientific Officer
• Robert Ross,
  Chief Medical Officer
• J. Jeffrey Goater,
  CEO, Pres & Director
• Dr. Robert W. Ross,
  Chief Medical Officer
• Daniel Lynch,
  Executive Chairman of the Board
• Laurie Stelzer,
  Independent Director
• Cameron McDonough,
  Independent Director
• Armen Shanafelt,
  Independent Director
• David Grayzel,
  Independent Director
• Elliott Sigal,
  Independent Director
• Ramy Ibrahim,
  Independent Director
• Liisa Nogelo,
  Chief Legal Officer, Secretary
• Wendy Dwyer,
  Chief Business Officer
• Jessica Fees,
  Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer
• Alison O'Neill,
  Sr. VP of Clinical Devel.
• Bob Steininger,
  Sr. VP of Chemistry, Manufacturing & Controls
• Lisa McGrath,
  Sr. VP of HR
• Liisa I. Nogelo,
  Sec., Chief Compliance Officer & Chief Legal Officer
• Jessica Fees,
  Sr. VP of Fin. & Treasurer
• Carsten Brunn,
  Director
• Theresa Boni,
  General Counsel & Secretary
• Enterprise Associates 14, L...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Institutes For Bio Medical ...,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Management Group, Llc Lilly...,
  
• Peter W. Sonsini,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 14, L...,
  10% owner
• 2017 Liquidating Trust Kear...,
  
• Llc Fmr,
  
• Ltd Fil,
  
• Geoff Mcdonough,
  Director
• Capital, Llc Eco R1,
  10% owner
• Alison Oneill,
  Chief Medical Officer
• Henry C. Rath,
  Chief Business Officer
• Denice Torres,
  Director
• Benjamin Hickey,
  Director
• Chandra Adams,
  Deputy GC